Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agile Therapeutics, a late-stage pharmaceutical company specializing in women's health products, has received two patents for its proprietary transdermal delivery technology from the US Patent and Trademark Office.
Subscribe to our email newsletter
The patents for the company’s Skinfusion technology cover the intermediate formulation during manufacturing and the finished product for a transdermal patch containing estrogen and progestin used in contraception.
Agile’s lead product, AG200-15, is a new, innovative, low-dose, weekly contraceptive patch entering Phase III clinical development. The patch will provide women with a convenient alternative to oral contraceptives by avoiding the need to remember to take a pill every day.
According to the company, Skinfusion technology utilizes passive enhancement chemistry in a dual delivery system consisting of an active and peripheral adhesive system that delivers hormones at levels necessary to prevent pregnancy.
The company has filed an additional patent application covering the active adhesive system, which utilizes a unique combination of enhancers to provide balanced delivery of drug over seven days. In addition, patent applications have been filed to protect intellectual property rights in the peripheral adhesive system, which maintains drug stability while improving patch adhesion and comfort.
Thomas Rossi, president and CEO of Agile Therapeutics, said: “Skinfusion technology is a significant advancement in contraception, providing women with the hormonal combination of levonorgestrel and ethinyl estradiol in a low-dose, weekly contraceptive patch that is comfortable to wear. We expect our patents to protect this important asset for Agile well into the future.”